RxDoctor Payments Data

Shadi Resheidat, MD

Family Medicine · Lafayette, INNPI 1790895571

Payments from drug & device makers

$6,600in general payments, 2019–2025

Across 436 payments — averaging $15.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$944
  • Lilly USA, LLC$814
  • Pfizer$681
  • AstraZeneca$623
  • Johnson & Johnson$301
  • plus $2K from 42 others

What the payments were for

  • Food & beverage$6,55399%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,600 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$81,515
Medicare patients
191
Services billed
2,008

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin106$149,299
OzempicSemaglutide116$137,946
EliquisApixaban68$72,316
XareltoRivaroxaban36$45,378
TrulicityDulaglutide31$39,679
RybelsusSemaglutide25$33,271
MyrbetriqMirabegron31$29,867
MounjaroTirzepatide24$24,221
InvokanaCanagliflozin14$22,722
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$16,495
EntrestoSacubitril/Valsartan12$16,050
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$15,572
Synjardy XrEmpagliflozin/Metformin Hcl13$7,784
Varenicline Tartrate21$4,971
DuleraMometasone/Formoterol12$4,209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,064$171,217141 claims
Boehringer IngelheimJardiance, Synjardy Xr$176$157,083119 claims
PfizerEliquis$681$72,31668 claims
Johnson & JohnsonXarelto, Invokana$301$68,10050 claims
Lilly USA, LLCTrulicity, Mounjaro$814$63,90055 claims
Astellas Pharma US IncMyrbetriq$74$29,86731 claims
GSKTrelegy Ellipta$155$16,49525 claims
NovartisEntresto$83$16,05012 claims
AstraZenecaBreztri Aerosphere$623$15,57216 claims
MerckDulera$57$4,20912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Lafayette

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →